UK markets closed

Transgene SA (0OCQ.L)

LSE - LSE Delayed price. Currency in EUR
Add to watchlist
2.4761-0.0989 (-3.84%)
At close: 4:57PM BST
Full screen
Previous close2.5750
Open2.4498
Bid0.0000 x 0
Ask0.0000 x 0
Day's range2.4498 - 2.4761
52-week range2.4498 - 2.4761
Volume4,691
Avg. volumeN/A
Market cap154.442M
Beta (5Y monthly)0.97
PE ratio (TTM)N/A
EPS (TTM)-0.2100
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Business Wire

    Availability of Transgene’s Half-Year Financial Report as of June 30, 2021

    STRASBOURG, France, September 22, 2021--Regulatory News: TRANSGENE (Paris:TNG) today announced that it has made available to the public and filed with the Autorité des marchés financiers its half-year financial report as of June 30, 2021.

  • Business Wire

    Transgene’s Two Innovative Platforms Progressing Well - Financial Visibility Extended Until End 2023

    STRASBOURG, France, September 22, 2021--Regulatory News: Transgene (Paris:TNG) (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today publishes its financial results for the six-month period ended June 30, 2021, and provides an update on the progress of its portfolio of clinical-stage drug candidates.

  • Business Wire

    Transgene Presents Data From Phase I Clinical Trial Confirming the Potential of the Oncolytic Virus TG6002

    STRASBOURG, France, September 16, 2021--Regulatory News: Transgene (Paris:TNG) (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, today announces the presentation of data from a Phase I study combining intravenous (IV) oncolytic virus TG6002 and oral 5-FC in patients with advanced gastrointestinal carcinomas at the European Society for Medical Oncology (ESMO) virtual meeting taking place from September 16-21, 2021.